Compare RBBN & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | CMPX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.1M | 752.4M |
| IPO Year | 2000 | N/A |
| Metric | RBBN | CMPX |
|---|---|---|
| Price | $2.89 | $4.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $6.00 | ★ $13.44 |
| AVG Volume (30 Days) | 700.0K | ★ 1.8M |
| Earning Date | 10-22-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $868,592,000.00 | N/A |
| Revenue This Year | $5.02 | N/A |
| Revenue Next Year | $5.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.38 | N/A |
| 52 Week Low | $2.72 | $1.33 |
| 52 Week High | $5.38 | $5.86 |
| Indicator | RBBN | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 49.43 |
| Support Level | $2.86 | $4.83 |
| Resistance Level | $3.00 | $5.32 |
| Average True Range (ATR) | 0.10 | 0.31 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 48.44 | 16.76 |
Ribbon Communications Inc provides network solutions to service providers and enterprises. The company enables service providers and enterprises to modernize their communications networks and provide secure real-time communications solutions to their customers and employees. The company has two separate lines of business; the Cloud and Edge segment, and the IP Optical Networks segment. The majority of the revenue for the company is generated from its Cloud and Edge segment that provides secure and reliable software and hardware products, solutions, and services for VoIP communications, Voice Over LTE among others to service providers and enterprise customers. The company generates majority of its revenue from United States.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.